Participants
Deal Summary
TORL BioTherapeutics LLC closed a $96 million Series C financing to advance its antibody-based immunotherapies, including the CLDN6-targeted ADC TORL-1-23. The company is a clinical-stage biotech focusing on cancer treatments and will present updated Phase 1 results at ESMO 2025.
Comments
Want to join the conversation?
Loading comments...